Kancera AB (publ) (KAN.ST)

3.4250 +0.0250 (+0.74%) At close: 05:29PM CEST

Kancera AB (publ)

Karolinska Institutet Science Park
Nanna Svartz Väg 4
Solna 171 65
Sweden
46 8 50 12 60 80
https://www.kancera.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Thomas Olin Ph.D.	CEO & Director	3.57M	N/A	1958
Mr. Hans Richter	Chief Financial Officer	N/A	N/A	1949
Dr. Martin Norin	Chief Operating Officer	N/A	N/A	1959
Mr. Peter Selin	Exec. VP of Corp. Devel.	N/A	N/A	1973
Dr. Niclas Brynne	Head of Clinical Devel.	N/A	N/A	1961
Dr. Torbjörn Lundström	Chief Medical Officer	N/A	N/A	1953

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.

Corporate Governance

Kancera AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.